Scarica l'app Stockscreener
4.7072
1.29%
0.0472
Precedente Chiudi:
$4.66
Aprire:
$4.65
Volume 24 ore:
928.78K
Relative Volume:
0.28
Capitalizzazione di mercato:
$1.29B
Reddito:
$8.10M
Utile/perdita netta:
$-92.72M
Rapporto P/E:
-13.18
EPS:
-0.3571
Flusso di cassa netto:
$-82.52M
1 W Prestazione:
-0.84%
1M Prestazione:
-10.10%
6M Prestazione:
+79.47%
1 anno Prestazione:
+208.50%
Intervallo 1D:
$4.63
$4.86
Intervallo di 1 settimana:
$4.43
$4.86
Portata 52W:
$1.05
$6.02
Taysha Gene Therapies Inc Stock (TSHA) Company Profile
Nome
Taysha Gene Therapies Inc
Settore
Industria
Telefono
(214) 612-0000
Indirizzo
3000 PEGASUS PARK DRIVE, DALLAS
Confronta TSHA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TSHA
Taysha Gene Therapies Inc
|
4.715 | 1.28B | 8.10M | -92.72M | -82.52M | -0.3571 |
|
VRTX
Vertex Pharmaceuticals Inc
|
466.23 | 119.76B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
762.23 | 79.35B | 14.34B | 4.50B | 3.88B | 41.57 |
|
ARGX
Argen X Se Adr
|
847.29 | 51.71B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
350.76 | 44.80B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
345.36 | 38.18B | 4.98B | 69.60M | 525.67M | 0.5198 |
Taysha Gene Therapies Inc Stock (TSHA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-21 | Iniziato | Raymond James | Strong Buy |
| 2025-07-11 | Iniziato | BofA Securities | Buy |
| 2024-06-27 | Iniziato | BMO Capital Markets | Outperform |
| 2024-04-09 | Iniziato | Piper Sandler | Overweight |
| 2023-02-01 | Downgrade | Jefferies | Buy → Hold |
| 2023-01-27 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2022-11-09 | Downgrade | Goldman | Buy → Neutral |
| 2022-03-09 | Iniziato | Robert W. Baird | Outperform |
| 2022-03-01 | Iniziato | Wells Fargo | Overweight |
| 2022-02-18 | Iniziato | SMBC Nikko | Outperform |
| 2021-12-16 | Iniziato | Guggenheim | Buy |
| 2021-07-16 | Iniziato | Needham | Buy |
| 2021-06-24 | Iniziato | Truist | Buy |
| 2021-06-15 | Iniziato | BTIG Research | Buy |
| 2021-06-09 | Iniziato | Wedbush | Outperform |
| 2021-06-08 | Iniziato | JMP Securities | Mkt Outperform |
| 2021-05-19 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-05-11 | Ripresa | Jefferies | Buy |
| 2021-02-24 | Iniziato | William Blair | Outperform |
| 2021-01-05 | Iniziato | Oppenheimer | Outperform |
| 2020-10-19 | Iniziato | Chardan Capital Markets | Buy |
| 2020-10-19 | Iniziato | Goldman | Buy |
| 2020-10-19 | Iniziato | Jefferies | Buy |
| 2020-10-19 | Iniziato | Morgan Stanley | Overweight |
Mostra tutto
Taysha Gene Therapies Inc Borsa (TSHA) Ultime notizie
Cell And Gene Therapy Enters ‘Disciplined Growth Cycle’ As Commercial Momentum Builds - Citeline News & Insights
Taysha Gene Therapies, Inc. (TSHA) Gains Wells Fargo’s Support on Rett Syndrome Program Progress - Insider Monkey
Taysha Gene Therapies, Inc. (TSHA) Gains Wells Fargo's Support on Rett Syndrome Program Progress - Finviz
Institution Moves: Does Taysha Gene Therapies Inc have strong fundamentals2025 Retail Activity & Stepwise Swing Trade Plans - baoquankhu1.vn
Taysha Gene Therapies, Inc. $TSHA Shares Sold by SG Americas Securities LLC - MarketBeat
Activity Recap: How cyclical is Taysha Gene Therapies Incs revenue streamWeekly Stock Report & Precise Trade Entry Recommendations - baoquankhu1.vn
Pivotal Trial for Taysha's Rett Syndrome Gene Therapy TSHA-102 Doses First Patient - CGTLive®
Taysha Doses First Patient in Pivotal Trial for Rett Syndrome Gene Therapy TSHA-102, Aligns With FDA on BLA Plans - NeurologyLive
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
10 Best Strong Buy Stocks to Invest In Under $5 - Insider Monkey
Here’s What Analysts Are Saying About Taysha Gene Therapies (TSHA) - Insider Monkey
Taysha Gene Therapies (NASDAQ:TSHA) CEO Sells $649,747.75 in Stock - MarketBeat
Insider Selling: Taysha Gene Therapies (NASDAQ:TSHA) CEO Sells 41,312 Shares of Stock - MarketBeat
Insider Selling: Taysha Gene Therapies (NASDAQ:TSHA) Insider Sells 26,918 Shares of Stock - MarketBeat
Insider Selling: Taysha Gene Therapies (NASDAQ:TSHA) Insider Sells 89,132 Shares of Stock - MarketBeat
Taysha Gene Therapies, Inc. (TSHA) Reports Q1 Loss, Tops Revenue Estimates - sharewise.com
Taysha Gene Therapies (NASDAQ:TSHA) Trading Down 6.2%What's Next? - MarketBeat
Taysha Gene Therapies Targets Genetic Neurological Conditions - Kalkine Media
Taysha Gene Therapies commences underwritten public offering - MSN
Dip Buying: How liquid is Taysha Gene Therapies Inc stock2025 Support & Resistance & Entry Point Strategy Guides - baoquankhu1.vn
Trading Recap: Can PBYI generate free cash flowJuly 2025 Rallies & Free Fast Entry Momentum Trade Alerts - baoquankhu1.vn
VIX Spike: Is Taysha Gene Therapies Inc stock good for income investors2025 Sector Review & Technical Entry and Exit Tips - baoquankhu1.vn
Insider Selling: Taysha Gene Therapies (NASDAQ:TSHA) Insider Sells 200,000 Shares of Stock - MarketBeat
Nagendran sells Taysha gene therapies (TSHA) stock for $942k By Investing.com - Investing.com Canada
Taysha Gene Therapies Inc. (TSHA): A Promising Biotech on Rett Syndrome Drug Prospects - Insider Monkey
10 Best Penny Stocks to Buy for 2026 - Insider Monkey
Buybacks Report: What is KIDSs TAM Total Addressable MarketIPO Watch & Safe Swing Trade Setup Alerts - baoquankhu1.vn
Taysha Gene Therapies (NASDAQ:TSHA) Trading Down 6.3%Should You Sell? - MarketBeat
Taysha Gene Therapies Advances TSHA-102 Program - MSN
Taysha Gene Therapies (TSHA) Stock Analysis: Unveiling a 114% Potential Upside in Biotech Innovation - DirectorsTalk Interviews
Is Taysha Gene Therapies Inc. stock a buy on dipsMarket Volume Report & High Conviction Investment Ideas - ulpravda.ru
Is Taysha Gene Therapies Inc. stock attractive for long term wealth buildingJuly 2025 Earnings & Detailed Earnings Play Alerts - ulpravda.ru
Is Taysha Gene Therapies Inc. stock vulnerable to regulatory risks2025 Technical Patterns & Fast Exit and Entry Strategy Plans - Улправда
Is Taysha Gene Therapies Inc. stock a bargain at current levelsJuly 2025 Summary & Verified Chart Pattern Signals - Улправда
Can Taysha Gene Therapies Inc. stock beat analyst upgradesMarket Performance Report & High Conviction Buy Zone Alerts - ulpravda.ru
Can Taysha Gene Therapies Inc. stock rebound after recent weaknessJuly 2025 PreEarnings & Smart Money Movement Alerts - Улправда
Should I hold or sell Taysha Gene Therapies Inc. stock in 2025July 2025 Action & Reliable Entry Point Alerts - Улправда
Will Taysha Gene Therapies Inc. stock benefit from green energy trendsJuly 2025 Recap & Low Risk High Win Rate Picks - ulpravda.ru
Pivotal trial of Rett gene therapy TSHA-102 now underway, and recruiting - Rett Syndrome News
Taysha doses first patient in pivotal Rett syndrome gene therapy trial - Investing.com Nigeria
Chardan Capital Maintains Buy Rating on TSHA at $12 | TSHA Stock News - GuruFocus
Raymond James reiterates Strong Buy on Taysha Gene Therapies stock By Investing.com - Investing.com Canada
Taysha doses first patient in pivotal Rett syndrome gene therapy trial By Investing.com - Investing.com South Africa
Taysha Gene Therapies (TSHA) Advances in Rett Syndrome Gene Ther - GuruFocus
Taysha Gene Therapies Announces Progress Across TSHA-102 Pivotal Gene Therapy Program in Rett Syndrome - The Manila Times
Taysha Gene Therapies, Inc.Common Stock (NQ: TSHA - FinancialContent
Wells Fargo Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Cuts Target Price to $11 - 富途牛牛
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Taysha Gene Therapies (NASDAQ:TSHA) Cut to "Sell" at Wall Street Zen - MarketBeat
Aug Highlights: Can Taysha Gene Therapies Inc stock rebound after recent weaknessIPO Watch & Precise Buy Zone Tips - moha.gov.vn
Taysha Gene Therapies (NASDAQ:TSHA) Shares Down 4.8%What's Next? - MarketBeat
Taysha Gene Therapies Inc Azioni (TSHA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Taysha Gene Therapies Inc Azioni (TSHA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Nagendran Sukumar | President and Head of R&D |
Jan 26 '26 |
Sale |
4.61 |
26,918 |
124,092 |
1,317,389 |
| Nolan Sean P. | Chief Executive Officer |
Jan 23 '26 |
Sale |
4.75 |
136,789 |
649,748 |
2,949,569 |
| Nolan Sean P. | Chief Executive Officer |
Jan 26 '26 |
Sale |
4.61 |
41,312 |
190,448 |
2,908,257 |
| Alam Kamran | CHIEF FINANCIAL OFFICER |
Jan 23 '26 |
Sale |
4.75 |
78,968 |
375,098 |
1,467,635 |
| Alam Kamran | CHIEF FINANCIAL OFFICER |
Jan 26 '26 |
Sale |
4.61 |
23,849 |
109,944 |
1,443,786 |
1.53%
1.92%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):